240 related articles for article (PubMed ID: 25768946)
1. Clonality and evolutionary history of rhabdomyosarcoma.
Chen L; Shern JF; Wei JS; Yohe ME; Song YK; Hurd L; Liao H; Catchpoole D; Skapek SX; Barr FG; Hawkins DS; Khan J
PLoS Genet; 2015 Mar; 11(3):e1005075. PubMed ID: 25768946
[TBL] [Abstract][Full Text] [Related]
2. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
3. Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.
Teot LA; Schneider M; Thorner AR; Tian J; Chi YY; Ducar M; Lin L; Wlodarski M; Grier HE; Fletcher CDM; van Hummelen P; Skapek SX; Hawkins DS; Wagers AJ; Rodriguez-Galindo C; Hettmer S
Cancer; 2018 May; 124(9):1973-1981. PubMed ID: 29461635
[TBL] [Abstract][Full Text] [Related]
4. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
[TBL] [Abstract][Full Text] [Related]
5. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
[TBL] [Abstract][Full Text] [Related]
6. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
Shern JF; Chen L; Chmielecki J; Wei JS; Patidar R; Rosenberg M; Ambrogio L; Auclair D; Wang J; Song YK; Tolman C; Hurd L; Liao H; Zhang S; Bogen D; Brohl AS; Sindiri S; Catchpoole D; Badgett T; Getz G; Mora J; Anderson JR; Skapek SX; Barr FG; Meyerson M; Hawkins DS; Khan J
Cancer Discov; 2014 Feb; 4(2):216-31. PubMed ID: 24436047
[TBL] [Abstract][Full Text] [Related]
8. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
[TBL] [Abstract][Full Text] [Related]
9. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.
de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR
Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386
[TBL] [Abstract][Full Text] [Related]
10. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
[TBL] [Abstract][Full Text] [Related]
11. MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells.
Cassandri M; Pomella S; Rossetti A; Petragnano F; Milazzo L; Vulcano F; Camero S; Codenotti S; Cicchetti F; Maggio R; Festuccia C; Gravina GL; Fanzani A; Megiorni F; Catanoso M; Marchese C; Tombolini V; Locatelli F; Rota R; Marampon F
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639012
[TBL] [Abstract][Full Text] [Related]
12. Molecular diagnostics in the management of rhabdomyosarcoma.
Arnold MA; Barr FG
Expert Rev Mol Diagn; 2017 Feb; 17(2):189-194. PubMed ID: 28058850
[TBL] [Abstract][Full Text] [Related]
13. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].
Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543
[TBL] [Abstract][Full Text] [Related]
14. Molecular Cytogenetics Detect an Unbalanced t(2;13)(q36;q14) and PAX3-FOXO1 Fusion in Rhabdomyosarcoma With Mixed Embryonal/Alveolar Features.
La Starza R; Nofrini V; Pierini T; Pierini V; Zin A; Bisogno G; Cerri C; Caniglia M; Sidoni A; Ludwig K; Mecucci C
Pediatr Blood Cancer; 2015 Dec; 62(12):2238-41. PubMed ID: 26179572
[TBL] [Abstract][Full Text] [Related]
15. A study of alveolar rhabdomyosarcoma copy number alterations by single nucleotide polymorphism analysis.
Lynn M; Shah N; Conroy J; Ennis S; Morris T; Betts D; O'Sullivan M
Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):213-21. PubMed ID: 24614150
[TBL] [Abstract][Full Text] [Related]
16. Uncovering metabolism in rhabdomyosarcoma.
Monti E; Fanzani A
Cell Cycle; 2016; 15(2):184-95. PubMed ID: 26209235
[TBL] [Abstract][Full Text] [Related]
17. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.
Selfe J; Olmos D; Al-Saadi R; Thway K; Chisholm J; Kelsey A; Shipley J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035744
[TBL] [Abstract][Full Text] [Related]
18. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.
Seki M; Nishimura R; Yoshida K; Shimamura T; Shiraishi Y; Sato Y; Kato M; Chiba K; Tanaka H; Hoshino N; Nagae G; Shiozawa Y; Okuno Y; Hosoi H; Tanaka Y; Okita H; Miyachi M; Souzaki R; Taguchi T; Koh K; Hanada R; Kato K; Nomura Y; Akiyama M; Oka A; Igarashi T; Miyano S; Aburatani H; Hayashi Y; Ogawa S; Takita J
Nat Commun; 2015 Jul; 6():7557. PubMed ID: 26138366
[TBL] [Abstract][Full Text] [Related]
19. Signaling pathways in Rhabdomyosarcoma invasion and metastasis.
Ramadan F; Fahs A; Ghayad SE; Saab R
Cancer Metastasis Rev; 2020 Mar; 39(1):287-301. PubMed ID: 31989508
[TBL] [Abstract][Full Text] [Related]
20. Cancer-Specific Energy Metabolism in Rhabdomyosarcoma Cells Is Regulated by MicroRNA.
Sugito N; Taniguchi K; Kuranaga Y; Ohishi M; Soga T; Ito Y; Miyachi M; Kikuchi K; Hosoi H; Akao Y
Nucleic Acid Ther; 2017 Dec; 27(6):365-377. PubMed ID: 28981396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
